Company Profile
ANI Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- ANIP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
82.63 USD (+3.44%)
Close
Last updated: August 6, 2026
1.7B USD
Market cap
Why the stock is moving
The latest monitored company update is “ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Rare-Disease and Specialty Pharmaceuticals
ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines.
Cortrophin Gel
Purified Cortrophin Gel is an adrenocorticotropic hormone therapy used across selected autoimmune and inflammatory indications. It is the primary growth driver of ANI's rare-disease franchise.
Ophthalmology Portfolio
ILUVIEN and YUTIQ are sustained-release fluocinolone implants for retinal diseases, including diabetic macular edema and chronic noninfectious uveitis affecting the posterior segment.
Future catalysts
Phase 4 SYNCHRONICITY results in noninfectious uveitis at a medical conference in the third quarter of 2026.
Recent news
- 01
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
Source: ANI Pharmaceuticals
- 02
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
Source: ANI Pharmaceuticals
- 03
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
Source: ANI Pharmaceuticals
- 04
- 05
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
Source: ANI Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ANI Pharmaceuticals (ANIP)?
ANI Pharmaceuticals (ANIP) most recently closed at 82.63 USD, a +3.44% move versus the previous session.
What is the market cap of ANI Pharmaceuticals (ANIP)?
ANI Pharmaceuticals currently has a market capitalization of 1.7B USD on BioPharmSignal.
What does ANI Pharmaceuticals do?
Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines. Cortrophin Gel Purified Cortrophin Gel is an adrenocorticotropic hormone therapy used across...
On which exchange is ANIP stock listed?
ANI Pharmaceuticals (ANIP) is associated with NASDAQ, United States, Biopharma.
What is Rare-Disease?
Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets.
Which conditions is ANI Pharmaceuticals targeting with Rare-Disease?
ANI Pharmaceuticals is associated with rare disease, ophthalmology based on its company overview and current catalyst commentary.
How does ANI Pharmaceuticals describe recent progress with Rare-Disease?
Phase 4 SYNCHRONICITY results in noninfectious uveitis at a medical conference in the third quarter of 2026.
What is Specialty?
Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets.